Insider Selling: Renovaro Inc. (NASDAQ:RENB) Major Shareholder Sells $22,006.50 in Stock

Renovaro Inc. (NASDAQ:RENB) major shareholder Anderson Wittekind William sold 14,671 shares of the company’s stock in a transaction dated Thursday, June 27th. The stock was sold at an average price of $1.50, for a total transaction of $22,006.50. Following the completion of the sale, the insider now directly owns 1,178,828 shares in the company, valued at $1,768,242. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Anderson Wittekind William also recently made the following trade(s):

• On Tuesday, June 25th, Anderson Wittekind William sold 20,000 shares of Renovaro stock. The shares were sold at an average price of $1.58, for a total transaction of $31,600.00.
• On Friday, June 14th, Anderson Wittekind William sold 50,000 shares of Renovaro stock. The shares were sold at an average price of $1.58, for a total transaction of $79,000.00.

Renovaro Stock Performance

Shares of RENB stock opened at $1.75 on Friday. Renovaro Inc. has a one year low of $0.39 and a one year high of $5.25. The company’s 50-day moving average is $1.43 and its 200 day moving average is $2.60. The company has a market capitalization of $258.14 million, a price-to-earnings ratio of -2.24 and a beta of 0.44.

Renovaro (NASDAQ:RENB) last announced its quarterly earnings data on Wednesday, May 15th. The company reported ($0.08) EPS for the quarter.

Institutional Trading of Renovaro

A number of institutional investors have recently made changes to their positions in RENB. SG Americas Securities LLC purchased a new stake in shares of Renovaro during the 1st quarter valued at about $46,000. Tidal Investments LLC purchased a new stake in shares of Renovaro during the 1st quarter valued at about $98,000. Finally, Vanguard Group Inc. boosted its holdings in shares of Renovaro by 904.0% during the 1st quarter. Vanguard Group Inc. now owns 3,916,672 shares of the company’s stock valued at $10,379,000 after acquiring an additional 3,526,565 shares during the last quarter. Hedge funds and other institutional investors own 71.41% of the company’s stock.

About Renovaro

Renovaro Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV.